STOCK TITAN

Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in September

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in September:

The LD 500 Virtual Investor Conference
September 3, 2020 at 12:20 p.m. ET
Registration: https://www.webcaster4.com/Webcast/Page/2019/36780 

H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020
September 16, 2020 at 1:30 p.m. ET
Registration: https://www.meetmax.com/sched/event_61861/investor_login.html?attendee_role_id=INVESTOR  

Sidoti & Company 2020 Fall Virtual Investor Conference
September 23, 2020 at 2:30 p.m. ET
Registration: https://sidoti.meetmax.com/sched/event_63793/conference_register.html?attendee_role_id=SIDOTI_INVESTOR 

Management will be available for 1x1 meetings with investors throughout each event. Please contact your conference representative to schedule a meeting. To stay up to date on upcoming events please check our calendar regularly: https://ir.hoththerapeutics.com/events/category/events/

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please click here.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com 
www.hoththerapeutics.com
Phone: (678) 570-6791  

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-participation-at-upcoming-investor-conferences-in-september-301120459.html

SOURCE Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc.

NASDAQ:HOTH

HOTH Rankings

HOTH Latest News

HOTH Stock Data

5.96M
4.10M
1.62%
6.98%
4.95%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About HOTH

hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio